Evolution of Surgical Management and Outcomes of Neuroendocrine Tumor Liver Metastases

Excerpt

There are more treatment options available to patients diagnosed today with neuroendocrine tumor liver metastases (NELM) than ever before. Over the past few decades, the increased use of somatostatin analogues, combination chemotherapy, liver-directed therapy, and PRRT has paralleled improvements in perioperative safety and surgical technique to revolutionize the care for patients with NETLM. There is still, however, much to be gained in oncologic outcomes and quality of life for our patients with NETLM. As systemic and liver-directed therapy continue to evolve, it will be increasingly important to quantify the outcomes of cytoreductive surgery and to identify optimal pathways for treatment sequencing. To answer these questions, it is helpful to gain a perspective of outcomes over time in the surgical management of this rare and heterogenous group of diseases. …